Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 2/20 | 0.41 |
| ▸ | PDE4B known ✓ | Q07343 | 2/20 | 0.41 |
| ▸ | PDE4D known ✓ | Q08499 | 2/20 | 0.41 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719248 | 0.91 | CYP11B2 (0.46) | CYP11B2CYP11B1HTR2BHTR6NPY5R | |
| SCHEMBL1719655 | 0.90 | DYRK1A (0.45) | DYRK1ACYP11B2CYP11B1HTR2BHTR6 | |
| SCHEMBL1719659 | 0.90 | DYRK1A (0.45) | DYRK1ACYP11B2CYP11B1HTR2BHTR6 | |
| SCHEMBL1719844 | 0.84 | DHODH (0.39) | DYRK1ACSNK2A2CSNK2BDHODHPDE4A | |
| SCHEMBL1720507 | 0.83 | CYP2C9 (0.47) | DYRK1ACYP11B2CYP11B1HTR2BHTR6 | |
| SCHEMBL1719856 | 0.81 | CYP11B2 (0.47) | CYP11B2CYP11B1HTR2BHTR6NPY5R | |
| SCHEMBL1719251 | 0.80 | CYP11B2 (0.46) | CYP11B2CYP11B1HTR2BHTR6NPY5R | |
| SCHEMBL1719247 | 0.80 | CYP11B2 (0.46) | CYP11B2CYP11B1HTR2BHTR6NPY5R | |
| SCHEMBL1723815 | 0.79 | DYRK1A (0.36) | DYRK1ACYP11B2CYP11B1HTR2BHTR6 | |
| SCHEMBL1723814 | 0.79 | DYRK1A (0.36) | DYRK1ACYP11B2CYP11B1HTR2BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173735-B1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-01-11 | — | — | EP | disclosed |
| US-7935707-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090012063-A1 | Novel imidazole derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012063-A1 | Novel imidazole derivatives | CCR2, CCR1, CCR3 | PDE4A 982/4885PDE4B 724/4885PDE4D 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.